Generalizability of the Nonalcoholic Steatohepatitis Clinical Research Network Histologic Scoring System for Nonalcoholic Fatty Liver Disease

被引:104
作者
Juluri, Ravi
Vuppalanchi, Raj [1 ]
Olson, John [3 ]
Uenalp, Aynur [4 ]
Van Natta, Mark L. [4 ]
Cummings, Oscar W. [2 ]
Tonascia, James [4 ]
Chalasani, Naga
机构
[1] Indiana Univ Sch Med, Regenstrief Hlth Ctr, Dept Med, Indianapolis, IN 46202 USA
[2] Indiana Univ Sch Med, Dept Pathol, Indianapolis, IN 46202 USA
[3] Witham Hlth Serv, Lebanon, IN USA
[4] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Ctr Clin Trials, Baltimore, MD USA
关键词
sampling error; liver biopsy; nonalcoholic steatohepatitis; PLACEBO-CONTROLLED TRIAL; SAMPLING VARIABILITY; METABOLIC SYNDROME; NATURAL-HISTORY; UNITED-STATES; BIOPSY; AMINOTRANSFERASE; PIOGLITAZONE; POPULATION; PREVALENCE;
D O I
10.1097/MCG.0b013e3181dd1348
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Goals and Background: The recently developed histologic scoring system for nonalcoholic fatty liver disease (NAFLD) by the nonalcoholic steatohepatitis (NASH) Clinical Research Network (CRN) is becoming increasingly popular. However, its generalizability to a community setting has not been evaluated. We conducted a study to compare a community general pathologist to an expert hepatopathologist in assessing NAFLD using the NASH CRN scoring system. Study: Forty-eight consecutive patients with suspected NAFLD underwent liver biopsy. Histologic features of interest such as steatosis, lobular inflammation, balloon degeneration, fibrosis, NAFLD Activity Score (NAS), and the presence of NASH were scored in a blinded fashion by the 2 pathologists on 2 separate occasions 3 months apart. Results: The mean (+/- SD) length of the liver biopsy samples was 25 +/- 5 mm. Interobserver agreement (kappa) between 2 pathologists was 0.62 (0.45-0.80) for steatosis, 0.44 (0.23-0.65) for lobular inflammation, 0.25 (0.11-0.38) for ballooning, 0.40 for NAS (0.28-0.52), and 0.35 (0.19-0.52) for fibrosis. The 2 pathologists diagnosed "definite NASH" in a similar proportion of patients (56% vs. 57%), but their interobserver agreement was only 0.46 (0.24-0.67) as they both diagnosed different levels of NASH (borderline vs. definite) in different subjects. Intraobserver agreement was generally comparable for steatosis, lobular inflammation, NAS, and diagnosis of NASH, but not for fibrosis. Conclusions: Clinically important differences exist between community general pathologist and expert hepatopathologist in assessing NAFLD using the NASH CRN scoring system. More studies are needed to investigate its suitability for community-based clinical practice.
引用
收藏
页码:55 / 58
页数:4
相关论文
共 20 条
[1]   The natural history of nonalcoholic fatty liver disease: A population-based cohort study [J].
Adams, LA ;
Lymp, JF ;
St Sauver, J ;
Sanderson, SO ;
Lindor, KD ;
Feldstein, A ;
Angulo, P .
GASTROENTEROLOGY, 2005, 129 (01) :113-121
[2]   Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis [J].
Aithal, Guruprasad P. ;
Thomas, James A. ;
Kaye, Philip V. ;
Lawson, Adam ;
Ryder, Stephen D. ;
Spendlove, Ian ;
Austin, Andrew S. ;
Freeman, Jan G. ;
Morgan, Linda ;
Weeber, Jonathan .
GASTROENTEROLOGY, 2008, 135 (04) :1176-1184
[3]   A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis [J].
Belfort, Renata ;
Harrison, Stephen A. ;
Brown, Kenneth ;
Darland, Celia ;
Finch, Joan ;
Hardies, Jean ;
Balas, Bogdan ;
Gastaldelli, Amalia ;
Tio, Fermin ;
Pulcini, Joseph ;
Berria, Rachele ;
Ma, Jennie Z. ;
Dwivedi, Sunil ;
Havranek, Russell ;
Fincke, Chris ;
DeFronzo, Ralph ;
Bannayan, George A. ;
Schenker, Steven ;
Cusi, Kenneth .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 355 (22) :2297-2307
[4]   Prevalence of hepatic steatosis in an urban population in the United States: Impact of ethnicity [J].
Browning, JD ;
Szczepaniak, LS ;
Dobbins, R ;
Nuremberg, P ;
Horton, JD ;
Cohen, JC ;
Grundy, SM ;
Hobbs, HH .
HEPATOLOGY, 2004, 40 (06) :1387-1395
[5]   Nonalcoholic steatohepatitis: Histologic features and clinical correlations with 30 blinded biopsy specimens [J].
Brunt, EM ;
Neuschwander-Tetri, BA ;
Oliver, D ;
Wehmeier, KR ;
Bacon, BR .
HUMAN PATHOLOGY, 2004, 35 (09) :1070-1082
[6]  
Brunt EM, 1999, AM J GASTROENTEROL, V94, P2467, DOI 10.1111/j.1572-0241.1999.01377.x
[7]  
Clark JM, 2003, AM J GASTROENTEROL, V98, P960, DOI 10.1111/j.1572-0241.2003.07486.x
[8]   Natural history of nonalcoholic steatohepatitis:: A longitudinal study of repeat liver biopsies [J].
Fassio, E ;
Alvarez, E ;
Domínguez, N ;
Landeira, G ;
Longo, C .
HEPATOLOGY, 2004, 40 (04) :820-826
[9]  
Harrison Stephen A, 2004, Clin Liver Dis, V8, P861, DOI 10.1016/j.cld.2004.06.008
[10]   Orlistat for Overweight Subjects with Nonalcoholic Steatohepatitis: A Randomized, Prospective Trial [J].
Harrison, Stephen A. ;
Fecht, Will ;
Brunt, Elizabeth M. ;
Neuschwander-Tetri, Brent A. .
HEPATOLOGY, 2009, 49 (01) :80-86